Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy-Reference-Cited by-同舟云学术

Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy

Published:2019-08-06 Issue:5 Volume:187 Page:638-641
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Manwani Richa¹^ORCID,Mahmood Shameem¹²,Sachchithanantham Sajitha¹²,Lachmann Helen J.¹,Gillmore Julian D.¹,Yong Kwee²^ORCID,Rabin Neil²,Popat Rakesh²^ORCID,Kyriakou Charalampia²,Worthington Sarah²,Sharpley Faye¹^ORCID,Smith Mark²,Shah Raakhee²,Cheesman Simon²,Hawkins Philip N.¹,Wechalekar Ashutosh D.¹²

Affiliation:

1. National Amyloidosis Centre University College London (Royal Free Campus) LondonUK

2. Department of Haematology University College London Hospitals London UK

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16122

Reference15 articles.

1. Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

2. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study